ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / ARGX / insiders
RVMD (55) BIIB (74) MRNA (60) BNTX (52) ⌘ Pro Terminal β†’

argenx SE (ARGX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$892.87 -0.56% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $890.27

argenx SE (ARGX) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

πŸ“Š Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY) β†’
ROARABLE C β€’ HOLD / WATCH Cap $55.72B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARGX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ARGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, argenx SE (NASDAQ: ARGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $892.87 (-0.56% 1D, market cap $55.72B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ARGX ranks #142 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ARGX compare to RVMD and BIIB in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARGX carries a Roarable C (63/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, RVMD (Revolution Medicines Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -28.6%, cap $40.78B) and BIIB (Biogen Inc.) posts a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARGX?
β–Ό

For argenx SE (ARGX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #142 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $890.28 (-0.29%)🧬 Cannibal Buyback (-1.24% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 15.8% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY β€’ 54.8% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C
025507510063
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk B
Cash (11)Whales (10)SEC (16)Macro (14)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+2.3% Base Target
$1126 Bull$913 Base$712 Bear
πŸ“¬ FREE ARGX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ARGX)Realized 20D OHLCV Swing Band: Β±6.1%
Deterministic 5-Pillar Attribution (63/100 Composite)
πŸ” WHY ARGX SCORES 63/100 (C) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–² #2 Bullish Driver: Macro Regime Fit+14/20 pts (22% of score)

FRED Regime Γ— Technicals: 56% of 52W Range β€’ RSI-14 at 51.7 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
55
Grade C$802.64+8.4% Next Q
Q2 (-2Q)
58
Grade C$869.72+1.5% Next Q
Q3 (-1Q)
60
Grade C$882.48+1.2% Next Q
Current
63
Grade C$892.87+0.9% Hist 90D Ξ±
Trajectory: C (55) β†’ C (63)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the ARGX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 63/100 (C) score, ARGX faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) β€” any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($938.51) or 200D SMA ($855.64) invalidates the momentum regime and cuts Target Base ($912.96) toward Bear Floor ($712.11).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARGXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œARGX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ARGX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ARGX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ARGX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ARGX Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ARGX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +10.08%πŸ“ HORIZONTAL RANGE
2026-11-02O $891.8H $897.9L $891.8C $892.9VOL 161.0K
RES: $1,192.1SUP: $775.6SMA50: $938.5SMA200: $855.6
$1,094.9$1,003.2$911.5$819.7$728.0RES $1,192.1SUP $775.6$892.92026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARGX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ARGX Butterfly Map β†’ + Track ARGX β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth

vs. +18.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ARGX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ARGX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARGX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARGX)

Health Care Rank #142 of 1016 βš”οΈ RVMD vs ARGX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ARGX vs. RVMD, BIIB, MRNA, BNTX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, argenx SE (ARGX) ranks #142 by composite RQD confidence (63/100, grade C) and #35 by equity capitalization ($55.72B). Within this direct 5-issuer industry benchmark cohort, BIIB leads on earnings valuation at 28.5x trailing P/E, while ARGX leads on capital efficiency and profitability with 9.9% ROIC and β€” gross margin. BIIB currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with ARGX at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ARGX ACTIVE
argenx SE
C 63/100 32.8x β€” 9.9% -0.56% $55.72B Benchmark Subject
RVMD
Revolution Medicines Inc.
D+ 55/100 β€” β€” -28.6% +0.55% $40.78B /rvmd-vs-argx β†’
BIIB
Biogen Inc.
B 74/100 28.5x 75.7% 6.4% +1.59% $36.90B /biib-vs-argx β†’
MRNA
Moderna Inc.
C- 60/100 β€” 55.3% -34.1% -0.47% $88.93B /mrna-vs-argx β†’
BNTX
BioNTech SE
D+ 52/100 32.8x β€” 9.9% -1.08% $22.39B /bntx-vs-argx β†’

2. ARGX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

argenx SE (ARGX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $55.72B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of β€”, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. ARGX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARGX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, argenx SE (NASDAQ: ARGX) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $892.87 (-0.56% 1D, market cap $55.72B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, ARGX ranks #142 in composite RQD confidence.

How does ARGX compare to RVMD and BIIB in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ARGX carries a Roarable C (63/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, RVMD (Revolution Medicines Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -28.6%, cap $40.78B) and BIIB (Biogen Inc.) posts a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ARGX?

For argenx SE (ARGX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #142 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ARGX trading relative to its 50-day, 200-day, and 52-week technical levels?

ARGX last traded at $892.87 (-0.56% on volume of 462,634 shares), positioning the stock -4.86% below its 50-day simple moving average ($938.51) and +4.35% above its 200-day simple moving average ($855.64). Across its 52-week range of $661.85 to $1,072.75, ARGX sits at the 56.2% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±6.1% ($838.40 to $947.34).

ARGX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are ARGX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ARGX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: ARGX RQD Cockpit ARGX 12M Forecast ARGX Earnings & Move ARGX Dividends & DRIP ARGX Insiders & 13F ARGX Whale Options ARGX Profit Sankey ARGX News & Why
ROARABLE RATING BRIEF β€’ RQD 63/100 (C) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

ARGX β€” argenx SE: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:08:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 63 / C, labeled "Roarable Hold β€” Fair / Balanced Risk-Reward," per the Roarable RQD rating. Across its five pillars:

  • Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this reflects ROIC of 9.9% and an FCF yield of 2.21%. Those figures indicate a moderate return on invested capital but a thin free-cash-flow yield relative to the $55.72B market cap, which places valuation weight on future cash generation.
  • Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, so institutional flow is a weaker support for the thesis than the other pillars.
  • Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The score is modestly below midpoint.
  • Macro Regime Fit: 14 / 20. Per the Roarable RQD rating, beta is 1.02 and the pillar reflects sector sensitivity. A beta near 1.0 means the stock has tended to move broadly with the market rather than amplifying it.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 3.74, Piotroski F is 8/9, and Debt/Equity is 0.39. This is the strongest pillar and the main offset to weaker cash-flow and flow metrics.

For a prospective investor, the rating describes a balanced setup. The balance sheet is the firmest support. Valuation is the main tradeoff: per the market data, P/E (TTM) is 32.8 and forward P/E is 27.6, with EV/EBITDA of 21, which prices in meaningful earnings growth. Upside drivers would be earnings delivery and sustained institutional accumulation; the weakest pillars (whale flow, insider conviction) are where the thesis is least confirmed. This is an analytical framing, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
897.85$55.72B32.827.62127.340%1.02$661.85 - $1072.759.9%

Open Questions

  • What specific late-stage trial was scrapped, and what is its revenue or pipeline significance for argenx?
  • What are the reported revenue, operating income, net income, FCF, cash, and debt figures across periods, given that the financials section is empty?
  • What is the analyst consensus rating and price target distribution behind the reference to targets of at least $1,200?
  • Why is gross margin recorded as 0%, and what does that reflect in the reporting?
  • Which institutions and insiders are accumulating or selling, given the empty holders section?

ARGX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for argenx SE (ARGX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ARGX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARGX Bull vs. Bear Conversation Board β€” What's Your Call at $892.87?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARGX 🐻 50% BEARISH CONVICTION
1. Pick Your Side on ARGX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $969.68 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is ARGX (C β€’ RQD 63/100) a Buy at $897.85?

Welcome to the ARGX (argenx SE) Roar Pit. Current RQD Composite is 63/100 (Roarable Hold β€” Fair / Balanced Risk-Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $754.19 (-16.0%)
Spot @ $897.85

Pump the brakes on ARGX β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ARGX, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless argenx SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $1,113.33 (+24.0%)
Spot @ $897.85

ARGX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ARGX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $897.85 (52-wk range $661.85 - $1072.75), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%